scispace - formally typeset
S

Scott M. Grundy

Researcher at University of Texas Southwestern Medical Center

Publications -  849
Citations -  246629

Scott M. Grundy is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Cholesterol & Lipoprotein. The author has an hindex of 187, co-authored 841 publications receiving 231821 citations. Previous affiliations of Scott M. Grundy include University of California, San Francisco & University of California, Davis.

Papers
More filters
Journal ArticleDOI

Relationship of Generalized and Regional Adiposity to Insulin Sensitivity in Men With NIDDM

TL;DR: It is concluded that NIDDM patients do not have excess intraperitoneal fat, but that their fat distribution favors more truncal and less peripheral subcutaneousFat, and for each level of total and regional adiposity, NIDs patients have a heightened state of insulin resistance.
Journal ArticleDOI

Effects of dietary cholesterol on the regulation of total body cholesterol in man.

TL;DR: In the majority of cases the accumulation of cholesterol in body pools was small because of adequate compensation by reexcretion plus reduced synthesis, but in a few patients large accumulations occurred on high cholesterol diets when absorption exceeded the compensatory mechanisms.
Journal ArticleDOI

Measurements of cholesterol turnover, synthesis, and absorption in man, carried out by isotope kinetic and sterol balance methods.

TL;DR: Estimates of daily synthesis of cholesterol in man are estimated by measuring the excretion of cholesterol and its conversion products during periods of controlled sterol intake (sterol balance method), using isotopic or chromatographic procedures (or a combination of the two).
Journal ArticleDOI

Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association.

TL;DR: The American Heart Association sponsored a scientific conference entitled “Prevention VI: Diabetes and Cardiovascular Disease” on January 18 to 20, 2001, in Orlando, Fla, to create a report that would assist the AHA in the development of an agenda to reduce cardiovascular diseases (CVDs) that are associated with diabetes.
Journal ArticleDOI

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)

TL;DR: Combination therapy with simvastatin 20 mg and fenofibrate 160 mg in patients with combined hyperlipidemia resulted in additional improvement in all lipoprotein parameters measured compared with simVastatin20 mg monotherapy and was well tolerated, and this combination therapy is a beneficial therapeutic option for managing combined hyper Lipidemia.